SEC 13F Intelligence

Highvista Strategies LLC / MLTX

Highvista Strategies LLC’s Moonlake Immunotherapeutics Position

Does Highvista Strategies LLC own Moonlake Immunotherapeutics (MLTX)? Yes — 194.0K shares worth $4M (+1.00% of its 13F portfolio) as of Q1 2026, up from 19.1K shares the prior filed quarter.

Position Value
$4M
Q1 2026
Shares
194.0K
% of Portfolio
+1.00%
Quarters Held
12
currently held

Position History MLTX

Reported value by quarter
Q1 ’23: $3MQ1 ’23Q2 ’23: $7MQ3 ’23: $3MQ3 ’23Q4 ’23: $4MQ1 ’24: $3MQ1 ’24Q2 ’24: $2MQ3 ’24: $2MQ3 ’24Q4 ’24: $2MQ1 ’25: $2MQ1 ’25Q2 ’25: $988,982Q3 ’25: $136,653Q3 ’25Q1 ’26: $4Mfilingsflow.com
QuarterSharesValue% of Portfolio
Q1 2026194.0K$4M+1.00%
Q3 202519.1K$136,653+0.03%
Q2 202521.0K$988,982+0.36%
Q1 202543.5K$2M+0.66%
Q4 202443.5K$2M+0.88%
Q3 202443.5K$2M+0.76%
Q2 202442.2K$2M+0.68%
Q1 202459.8K$3M+1.07%
Q4 202359.8K$4M+1.31%
Q3 202359.8K$3M+1.58%
Q2 2023129.7K$7M+3.03%
Q1 2023122.2K$3M+2.13%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Highvista Strategies LLC’s full portfolio or all institutional holders of MLTX.